<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875313</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-011</org_study_id>
    <nct_id>NCT03875313</nct_id>
  </id_info>
  <brief_title>Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and
      tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839
      with the PARP inhibitor talazoparib in participants with advanced/metastatic solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, dose-escalation and dose-expansion study. In Part 1,
      escalating doses of CB-839 will be paired with the standard dose of talazoparib in order to
      determine the maximum tolerated dose (MTD) and/or the RP2D of the regimen and to characterize
      the safety and tolerability profile of the combination in participants with
      advanced/metastatic solid tumors.

      In Part 2, the combination of CB-839 and talazoparib will be evaluated at the RP2D determined
      in Part 1 to evaluate the anti-cancer activity of the regimen in participants with
      advanced/metastatic clear cell RCC, TNBC or CRC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CB-839 in combination with talazoparib: Number of participants with treatment related adverse events</measure>
    <time_frame>Start of treatment to 28 days post treatment</time_frame>
    <description>Number of participants with treatment related adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose and/ or Recommended Phase 2 Dose</measure>
    <time_frame>Measured for Part 1 patients within the first 28 day cycle</time_frame>
    <description>Incidence and nature of dose-limiting toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of CB-839 and talazoparib</measure>
    <time_frame>At the beginning of cycle 2 (each cycle is 28 days)</time_frame>
    <description>Non-compartmental method of analysis will be used to analyze the plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of CB-839 in combination with talazoparib</measure>
    <time_frame>Approximately every 8 weeks until disease progression, approximately 18 months</time_frame>
    <description>Change in tumor size from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>CRC</condition>
  <condition>RCC</condition>
  <condition>ccRCC</condition>
  <arm_group>
    <arm_group_label>Cohort 1: CB-839 and Talazoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg CB-839 taken twice daily and 1 mg talazoparib taken daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: CB-839 and Talazoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg CB-839 taken twice daily and 1 mg talazoparib taken daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839</intervention_name>
    <description>CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.</description>
    <arm_group_label>Cohort 1: CB-839 and Talazoparib</arm_group_label>
    <arm_group_label>Cohort 2: CB-839 and Talazoparib</arm_group_label>
    <other_name>telaglenastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.</description>
    <arm_group_label>Cohort 1: CB-839 and Talazoparib</arm_group_label>
    <arm_group_label>Cohort 2: CB-839 and Talazoparib</arm_group_label>
    <other_name>Talzenna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (Part 1)

        -Documented incurable/locally advanced or metastatic solid tumors that have either relapsed
        or are refractory or intolerant to standard therapies of proven clinical benefit.

        (Part 2) Meets 1 of the 3 defined cohorts:

          -  Cohort 1: Documented incurable/locally advanced or metastatic ccRCC

          -  Cohort 2: Documented incurable/locally advanced or metastatic TNBC defined as ER, PR
             negative (&lt;1%) and HER2 negative (immunohistochemistry 0 to 1+ or fluorescence in situ
             hybridization [FISH] negative)

          -  Cohort 3: incurable/locally advanced or metastatic CRC

        For both Parts 1 &amp; 2:

          -  Recovery to baseline or â‰¤ Grade 1 CTCAE v.5.0 from toxicities related to the prior
             therapy

          -  Adequate renal, hepatic, and hematological function

          -  Per RECIST v1.1 evaluable disease (Part 1) or measurable disease (Part 2)

          -  Ability to provide written consent in accordance with federal, local and institutional
             guidelines

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

        Exclusion Criteria for both Parts 1 &amp; 2:

          -  Prior treatment with CB-839 or a PARP inhibitor

          -  Unable to received oral medications

          -  Active and/or untreated central nervous system metastasis. Patients with treated brain
             metastases must have (1) documented radiographic stability of at least 4 weeks
             duration demonstrated on baseline central nervous system (CNS) imaging prior to study
             treatment and (2) be symptomatically stable and off steroids for at least 2 weeks
             before administration of any study treatment.

          -  Major surgery within 28 days prior to first dose of study drug

          -  Receipt of any anticancer therapy within the following windows: small molecule
             tyrosine kinase inhibitor therapy (including investigational) within the prior 2 weeks
             or 5 half-lives prior to C1D1, whichever is longer; any type of anti-cancer antibody
             or cytotoxic chemotherapy within 4 weeks prior to C1D1; radiation therapy for bone
             metastasis within 2 weeks prior or any other external radiation therapy within 4 weeks
             prior to C1D1; patients with clinically relevant ongoing complications from prior
             radiation therapy are not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Whiting, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Administrator</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Likesar (Keisha) McCray</last_name>
      <phone>205-975-7265</phone>
      <email>lmccray@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Erica Stringer-Reasor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manali Bhavi, MD</last_name>
      <phone>404-778-1900</phone>
      <email>manali.ajay.bhave@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Manali Bhave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Haugland</last_name>
      <phone>319-384-5285</phone>
      <email>heidi-haugland@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Yousef Zakharia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lee, MD</last_name>
      <phone>617-724-4000</phone>
      <email>rjlee@partners.org</email>
    </contact>
    <investigator>
      <last_name>Richard Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Olmos</last_name>
      <phone>212-342-5162</phone>
    </contact>
    <investigator>
      <last_name>Kevin Kalinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Payal Raulji</last_name>
      <phone>713-745-2939</phone>
      <email>pmraulji@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@startsa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>20000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Broghammer</last_name>
      <phone>801-213-6232</phone>
      <email>Jill.Broghammer@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Neeraj Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See URL www.uwhealth.org/uw-carbone-cancer-center/cancer-connect/10310</last_name>
      <phone>608-262-5223</phone>
    </contact>
    <contact_backup>
      <phone>1-800-622-8922</phone>
    </contact_backup>
    <investigator>
      <last_name>Hamid Emamekhoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor Metabolism</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <keyword>CB-839</keyword>
  <keyword>telaglenastat</keyword>
  <keyword>talazoparib</keyword>
  <keyword>PARP Inhibitor</keyword>
  <keyword>DNA Damage</keyword>
  <keyword>DNA Repair</keyword>
  <keyword>Homologous recombination deficiency</keyword>
  <keyword>HRD</keyword>
  <keyword>BRCA 1</keyword>
  <keyword>BRCA 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

